Europe and U.S. Issues New Warnings on Gilenya
Although U.S. and European health regulators have supported the continued use of the multiple sclerosis (MS) pill Gilenya , last week they announced that the drug needed to carry stronger warnings on risks of serious adverse effects on the heart. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) launched an investigation into the safety of